Clarify Pharma PLC Notice of AGM (3351K)
05 Maio 2022 - 3:01AM
UK Regulatory
TIDMPSYC
RNS Number : 3351K
Clarify Pharma PLC
05 May 2022
Press Release
05 May 2022
Clarify Pharma PLC
("Clarify Pharma" or "the Company")
Notice of Annual General Meeting
Clarify Pharma (AQSE: PSYC), an investment vehicle specialising
in biotech and life sciences companies seeking to prove the safety
and efficacy of psychedelic-based substances, announces that it
will hold its Annual General Meeting ('AGM') at 11:00am on Monday
30th May 2022 at the offices of Fladgate LLP, 16 Great Queen
Street, London, England, WC2B 5DG.
Further details of the arrangements for this year's AGM are set
out in the Notice of AGM, which together with the Form of Proxy,
will be posted to shareholders today. The Notice of AGM will
shortly also be available on the Company's website.
The directors of Clarify Pharma plc accept responsibility for
this announcement.
For further information please contact:
Clarify Pharma
Jon Bixby via Tancredi +44 207 887 7633
Executive Chairman
------------------------------
First Sentinel
------------------------------
Corporate Adviser
Brian Stockbridge +44 7876 888 011
------------------------------
Tennyson Securities
------------------------------
Corporate Broker
Peter Krens +44 207 186 9030
------------------------------
Tancredi Intelligent Communication
------------------------------
Media Relations
Catrina Daly
Emma Hodges
Salamander Davoudi +44 7727 153 868
+44 7861 995 628
clarifypharma@tancredigroup.com +44 7957 549 906
------------------------------
About Clarify Pharma PLC:
Listed on the Aquis Stock Exchange in London, Clarify Pharma is
an investment vehicle focusing on investing in biotech and life
sciences companies seeking to prove the safety and efficacy of
psychedelic based substances. The Company looks to identify
investment opportunities in the life sciences sector within the UK,
Canada and other growing markets, with the objective of generating
long-term capital growth and building investments in an R&D
pipeline of companies which are discovering, developing, or
deploying safe and evidence-based psychedelic inspired medicines
and experiential therapies that alleviate mental health problems
and enhance wellbeing. The Company's Directors have an established
track record, experience and networks in the psychedelic,
cannabinoid and media industries, to drive value creation.
www.clarifypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXUSOORUOUVRAR
(END) Dow Jones Newswires
May 05, 2022 02:01 ET (06:01 GMT)
Clarify Pharma (AQSE:PSYC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Clarify Pharma (AQSE:PSYC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024